Berhouma M, Bahri K, Houissa S, Zemmel I, Khouja N, Aouidj L, Jemel H, Khaldi M
Service de neurochirurgieB (unité 501), hôpital neurologique et neurochirurgical Pierre-Wertheimer, 59 boulevard Pinel, 69677 Lyon cedex, France.
Neurochirurgie. 2009 Jun;55(3):293-302. doi: 10.1016/j.neuchi.2008.02.060. Epub 2008 Jun 5.
Intramedullary spinal cord tumors (IMSCT) are relatively rare neoplasms, accounting for less than 5% of all central nervous system tumors. The optimum management of these tumors still remains controversial. Many decades ago, partial surgical resection followed by radiotherapy was the conventional management for IMSCT. Nowadays, maximal surgical resection of IMSCT without adjuvant therapy is the rule. We discuss the management of our cohort of 45 patients and review retrospectively the surgical outcome and survival.
We reviewed the charts of 45 patients who underwent surgery for IMSCT in our institution since 1990. The study included 23 female and 22 male with a mean age of 28.7 years (range: 18 months-64 years). In 40 patients, the final diagnosis was based on the results of MR imaging. The cervical location of the tumor was the most common (20 cases). Surgical procedures included a gross-total resection in 31 cases, subtotal resection in six cases, partial resection in five cases and a biopsy in three cases. The large majority of patients had histologically-proven low-grade tumors composed essentially of astrocytomas (44,4%) and ependymomas (28,8%). There was no mortality related to surgery. Concerning the functional outcome at six months, we noted that 22.2% of our patients deteriorated, 47.3% stayed the same and 30.5% improved. We found that patients with mild or no preoperative deficits were exceptionally damaged by the surgical procedure.
The gold-standard treatment of IMSCT remains maximal microsurgical resection without adjuvant therapy. For malignant or rapidly recurrent IMSCT, the optimum management is still controversial. Determinant predictors for a good outcome after surgery of IMSCT are histological type of lesion, total removal of the tumor and a satisfactory neurological status before surgery.
脊髓髓内肿瘤(IMSCT)是相对罕见的肿瘤,占所有中枢神经系统肿瘤的比例不到5%。这些肿瘤的最佳治疗方案仍存在争议。几十年前,部分手术切除后放疗是IMSCT的传统治疗方法。如今,IMSCT的最大程度手术切除且不进行辅助治疗已成为常规做法。我们讨论了我们这组45例患者的治疗情况,并回顾性分析了手术结果和生存率。
我们回顾了自1990年以来在我们机构接受IMSCT手术的45例患者的病历。该研究包括23名女性和22名男性,平均年龄为28.7岁(范围:18个月至64岁)。40例患者的最终诊断基于磁共振成像结果。肿瘤位于颈椎部位最为常见(20例)。手术方式包括31例全切除、6例次全切除、5例部分切除和3例活检。绝大多数患者组织学证实为低级别肿瘤,主要由星形细胞瘤(44.4%)和室管膜瘤(28.8%)组成。无手术相关死亡病例。关于术后6个月的功能结果,我们注意到22.2%的患者病情恶化,47.3%的患者病情稳定,30.5%的患者病情改善。我们发现术前轻度或无功能缺损的患者手术过程中受到的损伤格外严重。
IMSCT的金标准治疗方法仍然是最大程度的显微手术切除且不进行辅助治疗。对于恶性或快速复发的IMSCT,最佳治疗方案仍存在争议。IMSCT手术后良好预后的决定性预测因素是病变的组织学类型、肿瘤的完全切除以及术前满意的神经功能状态。